Home » 論文ナビSCOPE » 機関×分野分析 » 【論文データ】公益財団法人がん研究会の腫瘍学分野の研究動向まとめ 【論文データ】公益財団法人がん研究会の腫瘍学分野の研究動向まとめ 論文ナビは研究者によって運営される論文解説プラットフォームです。このページでは、最近二年間(2016-2017)で発表された文献データを独自に収集・集計して分かりやすくまとめました。論文キーワードマップ、代表的な研究機関、頻出キーワード、分野のシェア、分野関連図、関連文献等により、今までない情報を提供します。 統計データ breast cancergastric cancernon-small-cell lung cancer (NSCLC)colorectal cancerchemotherapylung cancermetastatic colorectal canceresophageal cancerJapaneseS-1cisplatinsurvivalJapannivolumaboverall survivalKRAS mutationstomach neoplasmimmunotherapyclinical trialradiotherapyprognosisTAS-102small cell lung cancer (SCLC)microsatellite instabilitychemoradiotherapydocetaxeloutcomePD-L1immune checkpointefficacybevacizumabp53biomarkeralectinibanaplastic lymphoma kinase (ALK)prognostic factortyrosine kinase inhibitorretrospective studymetastasismethylationJapanese patientsfamilial adenomatous polyposisneoadjuvant chemotherapyBRAF mutationLynch syndromesquamous cell carcinoma (SCC)rectal cancerprediction modelmolecular targeted therapypaclitaxelepidermal growth factor receptor (EGFR)eribulingemcitabineincidenceadherenceC-reactive protein (CRP)salivary duct carcinomaerlotiniblocal recurrencecastration-resistant prostate cancerEwing sarcomaadjuvant therapypancreatic cancer5-fluorouracilcancer stem cellsbiliary tract cancerHER2endocrine therapypodoplaninrisk factorsurgeryneoadjuvant therapytotal colectomylaparoscopic surgerysafetyimmunohistochemistryfluorescence in situ hybridization (FISH)irinotecansoft tissue sarcomapazopanibinduction chemotherapyamrubicinearly gastric cancerbreast-conserving surgeryearly recurrenceesophagectomyepigeneticsBRAFheterogeneityK rasXELOXfeasibility studyserumpredictioncolorectal neoplasmsdrug therapysmokinglymphatic metastasisadjuvant chemotherapygastrectomypropensity score matchinghypopharyngeal cancermutationafatinibtrastuzumabelderly patientsprospective studyMUC-1TGF-betaZEB1IL-6IL-8lymphomaregistrationinduction therapylung cancer surgerycapecitabineNLRadrenal insufficiencyleptomeningeal carcinomatosislung metastasisgiant cell tumor of bonemetastasectomyAsianmitochondriahypoxiaHIF-1Hodgkin lymphomaresistancemammalian target of rapamycin (mTOR)Wntp21molecular targetextracellular vesiclesmicroRNAurothelial carcinomaurinepeptide vaccinepredictive biomarkerneutrophil-to-lymphocyte ratiopoor prognosishead and neck squamous cell carcinomacetuximabiterative reconstructionrecurrencedyspneaTNM classificationsentinel lymph nodemultivariate analysisoral squamous cell carcinomacadherinepithelial-mesenchymal transitionEBUS-TBNAmTOR signalingrapamycinenergy metabolismdisease-free survivalnext-generation sequencinghead and neck cancernutritionxCTDNA repairATMtransporterdeformable image registrationvalidationadvanced gastric cancerphase I studymonoclonal antibodycolon cancerlung adenocarcinomaimmune checkpoint inhibitorRhoAROCKandrogen receptormotilitymesotheliomaYAP1CD31CD8diffuse large B-cell lymphomaCD5renal cell carcinoma (RCC)targeted therapyphase II studyEML4 ALKkinase inhibitorpost-marketing surveillancehypercalcemiachronic lymphocytic leukemiaEGFR mutationPI3K inhibitorsolid tumorsmetastatic renal cell carcinomamaintenance therapyR-CHOPfebrile neutropenialymph node metastasisoverall response rate (ORR)bioequivalencepathologyrectumhepatocellular carcinoma (HCC)fulvestrantmetastatic breast cancerupper urinary tract urothelial carcinomanon-muscle-invasive bladder cancermantle-cell lymphomapolymorphismneutropeniaUHRF1LINE-1pneumothoraxbrachytherapygynecologic cancercarcinomasunitinibDCFrandomized trialprognostic markerCCL5regorafenibVEGF-Aaprepitantpalonosetronmultiple myelomadexamethasonecolorectal liver metastasesoxaliplatinendoscopic submucosal dissectiondesmoid tumorrenal functionzoledronic acidbone metastasisdenosumablate recurrenceramucirumabcolonoscopycanceranimal modeldrug developmentclinical outcomesorafenibRETCXCR4cancer-associated fibroblastCXCL12esophageal squamous cell carcinomaWarburg effectmicroenvironmentdevelopmenttherapymyeloproliferative neoplasmessential thrombocythemialong-term outcomepathological complete responsesentinel lymph node biopsyCIMPpolypplateletsplatelet aggregationneutralizing antibodyprostate cancerpositron emission tomography (PET)stereotactic radiotherapyprogression-free survivaladverse eventsenzalutamidepropensity score
